CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma

By sjmartinez • July 11, 2024

Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M. CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma. Blood Adv. 2024 Jul 10:bloodadvances.2024013863. doi: 10.1182/bloodadvances.2024013863. Epub ahead of print. PMID: 38985302.

Tags: Hematology/Oncology, Publications

Related Posts

Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014

Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, Shustik J, Schiller GJ, Ganguly S, Song K, Seet CS, Acosta-Rivera M, Bar[...]

Incidence trends in upper GI cancer in young adults: a nationwide time-trend analysis using 2001-2019 United States Cancer Statistics databases

Liang J, Rastegar R, El Helou M, Mathur K, Larson BK, Waters K, Vasireddy A, Randhawa N, Mubarak M, Advani R, Osipov A, Gong J,[...]

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher[...]